Is BDNF‐Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population‐based cohort study
There is little research on genetic risk for the extended psychosis phenotype ranging from psychotic experiences (PEs) to psychotic disorders (PDs). In this general population‐based prospective cohort study, the longitudinal associations between BDNF‐Val66Met polymorphism and the different levels of...
Gespeichert in:
| Veröffentlicht in: | American journal of medical genetics. Part B, Neuropsychiatric genetics Neuropsychiatric genetics, 2019-03, Vol.180 (2), p.113-121 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 121 |
|---|---|
| container_issue | 2 |
| container_start_page | 113 |
| container_title | American journal of medical genetics. Part B, Neuropsychiatric genetics |
| container_volume | 180 |
| creator | Kirli, Umut Binbay, Tolga Drukker, Marjan Elbi, Hayriye Kayahan, Bülent Gökçelli, Duygu Keskin Özkınay, Ferda Onay, Hüseyin Alptekin, Köksal van Os, Jim |
| description | There is little research on genetic risk for the extended psychosis phenotype ranging from psychotic experiences (PEs) to psychotic disorders (PDs). In this general population‐based prospective cohort study, the longitudinal associations between BDNF‐Val66Met polymorphism and the different levels of the extended psychosis phenotype were investigated. Addresses were contacted in a multistage clustered probability sampling frame covering 11 districts and 302 neighborhoods at baseline (n = 4011). A nested case‐control study (n = 366) recruited individuals with PEs and PDs as well as individuals with no psychotic symptoms. In this subgroup, blood sampling for genetic analysis and assessment of environmental exposures were carried out, followed by clinical re‐appraisal at follow‐up 6 years later (n = 254). The BDNF‐Val66Met polymorphism was significantly associated with the extended psychosis phenotype. The pattern of the association was that the BDNF‐Val66Met polymorphism impacted in a dose‐response but extra‐linear fashion, with stronger impact at the PD end of the extended psychosis phenotype. Associations were still significant after adjusting for sociodemographic factors and environmental exposures including life events, childhood adversity, socioeconomic status, urbanicity, and cannabis use. The BDNF‐Val66Met polymorphism may index susceptibility to expression of psychosis along a spectrum. |
| doi_str_mv | 10.1002/ajmg.b.32641 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2184326454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2184326454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3641-5fee5ce98051ec176233dd2efa0ab49bff668688130985cf9d240fe0a940004a3</originalsourceid><addsrcrecordid>eNp9kc1u1DAURi0EoqXtrmtkiS0z2IntJCvUlrYU9WcDVXeWY18zHiXjYDtts-sj8Bq8Fk-ChykVq65syUfnu74fQvuUzCkhxQe17L_P23lZCEZfoG3KeTFjNb95-XRndAu9iXFJSEl4Vb1GW0VT1bwS5Tb6dRbx4afLk98PP69VJ8QFJDz4bup9GBYu9ljF6LVTCQy-c2mBhzjphU9OY7gfIDhYaYhYrcx_L8ZFHwwE7MekfQ8f8fGtM2sS2-CzEws8gQoRD8HHAXRyt5Bjh7FTyflVHqZVMSdqv_Ah4ZhGM-2iV1Z1EfYezx307eT469Hn2fnV6dnRwflMl3kDM24BuIamJpyCppUoytKYAqwiqmVNa60QtahrWpKm5to2pmDEAlENI4QwVe6gdxtvnu3HCDHJpR_DKkfKgtZsvWfOMvV-Q-n8gxjAyiG4XoVJUiLXvch1L7KVf3vJ-NtH6dj2YJ7gf0VkgG2AO9fB9KxMHny5OD3ceP8Ayj6fag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2184326454</pqid></control><display><type>article</type><title>Is BDNF‐Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population‐based cohort study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kirli, Umut ; Binbay, Tolga ; Drukker, Marjan ; Elbi, Hayriye ; Kayahan, Bülent ; Gökçelli, Duygu Keskin ; Özkınay, Ferda ; Onay, Hüseyin ; Alptekin, Köksal ; van Os, Jim</creator><creatorcontrib>Kirli, Umut ; Binbay, Tolga ; Drukker, Marjan ; Elbi, Hayriye ; Kayahan, Bülent ; Gökçelli, Duygu Keskin ; Özkınay, Ferda ; Onay, Hüseyin ; Alptekin, Köksal ; van Os, Jim</creatorcontrib><description>There is little research on genetic risk for the extended psychosis phenotype ranging from psychotic experiences (PEs) to psychotic disorders (PDs). In this general population‐based prospective cohort study, the longitudinal associations between BDNF‐Val66Met polymorphism and the different levels of the extended psychosis phenotype were investigated. Addresses were contacted in a multistage clustered probability sampling frame covering 11 districts and 302 neighborhoods at baseline (n = 4011). A nested case‐control study (n = 366) recruited individuals with PEs and PDs as well as individuals with no psychotic symptoms. In this subgroup, blood sampling for genetic analysis and assessment of environmental exposures were carried out, followed by clinical re‐appraisal at follow‐up 6 years later (n = 254). The BDNF‐Val66Met polymorphism was significantly associated with the extended psychosis phenotype. The pattern of the association was that the BDNF‐Val66Met polymorphism impacted in a dose‐response but extra‐linear fashion, with stronger impact at the PD end of the extended psychosis phenotype. Associations were still significant after adjusting for sociodemographic factors and environmental exposures including life events, childhood adversity, socioeconomic status, urbanicity, and cannabis use. The BDNF‐Val66Met polymorphism may index susceptibility to expression of psychosis along a spectrum.</description><identifier>ISSN: 1552-4841</identifier><identifier>EISSN: 1552-485X</identifier><identifier>DOI: 10.1002/ajmg.b.32641</identifier><identifier>PMID: 29785763</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; BDNF ; Brain-derived neurotrophic factor ; Brain-Derived Neurotrophic Factor - genetics ; Brain-Derived Neurotrophic Factor - metabolism ; Cannabis ; Case-Control Studies ; Children ; Cohort analysis ; Cohort Studies ; environmental factors ; epidemiology ; extended psychosis phenotype ; Female ; Gene polymorphism ; Genetic analysis ; Genetic Predisposition to Disease - genetics ; Genetics ; Genotype ; Genotype & phenotype ; Health risk assessment ; Humans ; Longitudinal Studies ; Male ; Mental Disorders - genetics ; Middle Aged ; Phenotype ; Phenotypes ; Polymorphism ; Polymorphism, Single Nucleotide - genetics ; Population studies ; Population-based studies ; Prospective Studies ; Psychosis ; Psychotic Disorders - genetics ; Psychotic Disorders - physiopathology ; Risk Factors ; Sampling ; transdiagnostic psychosis phenotype</subject><ispartof>American journal of medical genetics. Part B, Neuropsychiatric genetics, 2019-03, Vol.180 (2), p.113-121</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3641-5fee5ce98051ec176233dd2efa0ab49bff668688130985cf9d240fe0a940004a3</citedby><cites>FETCH-LOGICAL-c3641-5fee5ce98051ec176233dd2efa0ab49bff668688130985cf9d240fe0a940004a3</cites><orcidid>0000-0001-9924-2672</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajmg.b.32641$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajmg.b.32641$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29785763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kirli, Umut</creatorcontrib><creatorcontrib>Binbay, Tolga</creatorcontrib><creatorcontrib>Drukker, Marjan</creatorcontrib><creatorcontrib>Elbi, Hayriye</creatorcontrib><creatorcontrib>Kayahan, Bülent</creatorcontrib><creatorcontrib>Gökçelli, Duygu Keskin</creatorcontrib><creatorcontrib>Özkınay, Ferda</creatorcontrib><creatorcontrib>Onay, Hüseyin</creatorcontrib><creatorcontrib>Alptekin, Köksal</creatorcontrib><creatorcontrib>van Os, Jim</creatorcontrib><title>Is BDNF‐Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population‐based cohort study</title><title>American journal of medical genetics. Part B, Neuropsychiatric genetics</title><addtitle>Am J Med Genet B Neuropsychiatr Genet</addtitle><description>There is little research on genetic risk for the extended psychosis phenotype ranging from psychotic experiences (PEs) to psychotic disorders (PDs). In this general population‐based prospective cohort study, the longitudinal associations between BDNF‐Val66Met polymorphism and the different levels of the extended psychosis phenotype were investigated. Addresses were contacted in a multistage clustered probability sampling frame covering 11 districts and 302 neighborhoods at baseline (n = 4011). A nested case‐control study (n = 366) recruited individuals with PEs and PDs as well as individuals with no psychotic symptoms. In this subgroup, blood sampling for genetic analysis and assessment of environmental exposures were carried out, followed by clinical re‐appraisal at follow‐up 6 years later (n = 254). The BDNF‐Val66Met polymorphism was significantly associated with the extended psychosis phenotype. The pattern of the association was that the BDNF‐Val66Met polymorphism impacted in a dose‐response but extra‐linear fashion, with stronger impact at the PD end of the extended psychosis phenotype. Associations were still significant after adjusting for sociodemographic factors and environmental exposures including life events, childhood adversity, socioeconomic status, urbanicity, and cannabis use. The BDNF‐Val66Met polymorphism may index susceptibility to expression of psychosis along a spectrum.</description><subject>Adult</subject><subject>Aged</subject><subject>BDNF</subject><subject>Brain-derived neurotrophic factor</subject><subject>Brain-Derived Neurotrophic Factor - genetics</subject><subject>Brain-Derived Neurotrophic Factor - metabolism</subject><subject>Cannabis</subject><subject>Case-Control Studies</subject><subject>Children</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>environmental factors</subject><subject>epidemiology</subject><subject>extended psychosis phenotype</subject><subject>Female</subject><subject>Gene polymorphism</subject><subject>Genetic analysis</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Genetics</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Mental Disorders - genetics</subject><subject>Middle Aged</subject><subject>Phenotype</subject><subject>Phenotypes</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide - genetics</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Prospective Studies</subject><subject>Psychosis</subject><subject>Psychotic Disorders - genetics</subject><subject>Psychotic Disorders - physiopathology</subject><subject>Risk Factors</subject><subject>Sampling</subject><subject>transdiagnostic psychosis phenotype</subject><issn>1552-4841</issn><issn>1552-485X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAURi0EoqXtrmtkiS0z2IntJCvUlrYU9WcDVXeWY18zHiXjYDtts-sj8Bq8Fk-ChykVq65syUfnu74fQvuUzCkhxQe17L_P23lZCEZfoG3KeTFjNb95-XRndAu9iXFJSEl4Vb1GW0VT1bwS5Tb6dRbx4afLk98PP69VJ8QFJDz4bup9GBYu9ljF6LVTCQy-c2mBhzjphU9OY7gfIDhYaYhYrcx_L8ZFHwwE7MekfQ8f8fGtM2sS2-CzEws8gQoRD8HHAXRyt5Bjh7FTyflVHqZVMSdqv_Ah4ZhGM-2iV1Z1EfYezx307eT469Hn2fnV6dnRwflMl3kDM24BuIamJpyCppUoytKYAqwiqmVNa60QtahrWpKm5to2pmDEAlENI4QwVe6gdxtvnu3HCDHJpR_DKkfKgtZsvWfOMvV-Q-n8gxjAyiG4XoVJUiLXvch1L7KVf3vJ-NtH6dj2YJ7gf0VkgG2AO9fB9KxMHny5OD3ceP8Ayj6fag</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Kirli, Umut</creator><creator>Binbay, Tolga</creator><creator>Drukker, Marjan</creator><creator>Elbi, Hayriye</creator><creator>Kayahan, Bülent</creator><creator>Gökçelli, Duygu Keskin</creator><creator>Özkınay, Ferda</creator><creator>Onay, Hüseyin</creator><creator>Alptekin, Köksal</creator><creator>van Os, Jim</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0001-9924-2672</orcidid></search><sort><creationdate>201903</creationdate><title>Is BDNF‐Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population‐based cohort study</title><author>Kirli, Umut ; Binbay, Tolga ; Drukker, Marjan ; Elbi, Hayriye ; Kayahan, Bülent ; Gökçelli, Duygu Keskin ; Özkınay, Ferda ; Onay, Hüseyin ; Alptekin, Köksal ; van Os, Jim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3641-5fee5ce98051ec176233dd2efa0ab49bff668688130985cf9d240fe0a940004a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>BDNF</topic><topic>Brain-derived neurotrophic factor</topic><topic>Brain-Derived Neurotrophic Factor - genetics</topic><topic>Brain-Derived Neurotrophic Factor - metabolism</topic><topic>Cannabis</topic><topic>Case-Control Studies</topic><topic>Children</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>environmental factors</topic><topic>epidemiology</topic><topic>extended psychosis phenotype</topic><topic>Female</topic><topic>Gene polymorphism</topic><topic>Genetic analysis</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Genetics</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Mental Disorders - genetics</topic><topic>Middle Aged</topic><topic>Phenotype</topic><topic>Phenotypes</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide - genetics</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Prospective Studies</topic><topic>Psychosis</topic><topic>Psychotic Disorders - genetics</topic><topic>Psychotic Disorders - physiopathology</topic><topic>Risk Factors</topic><topic>Sampling</topic><topic>transdiagnostic psychosis phenotype</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kirli, Umut</creatorcontrib><creatorcontrib>Binbay, Tolga</creatorcontrib><creatorcontrib>Drukker, Marjan</creatorcontrib><creatorcontrib>Elbi, Hayriye</creatorcontrib><creatorcontrib>Kayahan, Bülent</creatorcontrib><creatorcontrib>Gökçelli, Duygu Keskin</creatorcontrib><creatorcontrib>Özkınay, Ferda</creatorcontrib><creatorcontrib>Onay, Hüseyin</creatorcontrib><creatorcontrib>Alptekin, Köksal</creatorcontrib><creatorcontrib>van Os, Jim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>American journal of medical genetics. Part B, Neuropsychiatric genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kirli, Umut</au><au>Binbay, Tolga</au><au>Drukker, Marjan</au><au>Elbi, Hayriye</au><au>Kayahan, Bülent</au><au>Gökçelli, Duygu Keskin</au><au>Özkınay, Ferda</au><au>Onay, Hüseyin</au><au>Alptekin, Köksal</au><au>van Os, Jim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is BDNF‐Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population‐based cohort study</atitle><jtitle>American journal of medical genetics. Part B, Neuropsychiatric genetics</jtitle><addtitle>Am J Med Genet B Neuropsychiatr Genet</addtitle><date>2019-03</date><risdate>2019</risdate><volume>180</volume><issue>2</issue><spage>113</spage><epage>121</epage><pages>113-121</pages><issn>1552-4841</issn><eissn>1552-485X</eissn><abstract>There is little research on genetic risk for the extended psychosis phenotype ranging from psychotic experiences (PEs) to psychotic disorders (PDs). In this general population‐based prospective cohort study, the longitudinal associations between BDNF‐Val66Met polymorphism and the different levels of the extended psychosis phenotype were investigated. Addresses were contacted in a multistage clustered probability sampling frame covering 11 districts and 302 neighborhoods at baseline (n = 4011). A nested case‐control study (n = 366) recruited individuals with PEs and PDs as well as individuals with no psychotic symptoms. In this subgroup, blood sampling for genetic analysis and assessment of environmental exposures were carried out, followed by clinical re‐appraisal at follow‐up 6 years later (n = 254). The BDNF‐Val66Met polymorphism was significantly associated with the extended psychosis phenotype. The pattern of the association was that the BDNF‐Val66Met polymorphism impacted in a dose‐response but extra‐linear fashion, with stronger impact at the PD end of the extended psychosis phenotype. Associations were still significant after adjusting for sociodemographic factors and environmental exposures including life events, childhood adversity, socioeconomic status, urbanicity, and cannabis use. The BDNF‐Val66Met polymorphism may index susceptibility to expression of psychosis along a spectrum.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29785763</pmid><doi>10.1002/ajmg.b.32641</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9924-2672</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-4841 |
| ispartof | American journal of medical genetics. Part B, Neuropsychiatric genetics, 2019-03, Vol.180 (2), p.113-121 |
| issn | 1552-4841 1552-485X |
| language | eng |
| recordid | cdi_proquest_journals_2184326454 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged BDNF Brain-derived neurotrophic factor Brain-Derived Neurotrophic Factor - genetics Brain-Derived Neurotrophic Factor - metabolism Cannabis Case-Control Studies Children Cohort analysis Cohort Studies environmental factors epidemiology extended psychosis phenotype Female Gene polymorphism Genetic analysis Genetic Predisposition to Disease - genetics Genetics Genotype Genotype & phenotype Health risk assessment Humans Longitudinal Studies Male Mental Disorders - genetics Middle Aged Phenotype Phenotypes Polymorphism Polymorphism, Single Nucleotide - genetics Population studies Population-based studies Prospective Studies Psychosis Psychotic Disorders - genetics Psychotic Disorders - physiopathology Risk Factors Sampling transdiagnostic psychosis phenotype |
| title | Is BDNF‐Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population‐based cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T01%3A32%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20BDNF%E2%80%90Val66Met%20polymorphism%20associated%20with%20psychotic%20experiences%20and%20psychotic%20disorder%20outcome?%20Evidence%20from%20a%206%20years%20prospective%20population%E2%80%90based%20cohort%20study&rft.jtitle=American%20journal%20of%20medical%20genetics.%20Part%20B,%20Neuropsychiatric%20genetics&rft.au=Kirli,%20Umut&rft.date=2019-03&rft.volume=180&rft.issue=2&rft.spage=113&rft.epage=121&rft.pages=113-121&rft.issn=1552-4841&rft.eissn=1552-485X&rft_id=info:doi/10.1002/ajmg.b.32641&rft_dat=%3Cproquest_cross%3E2184326454%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2184326454&rft_id=info:pmid/29785763&rfr_iscdi=true |